VolitionRx Study Shows Elevated Nu.Q Biomarkers in 674 Trauma Patients with VTE
VolitionRx’s Nu.Q H3.1 and H3R8 Citrulline assay detected elevated nucleosome levels in 674 trauma patients, with highest concentrations in those developing venous thromboembolism. Peer-reviewed clinical validation with Mayo Clinic bolsters VolitionRx’s Nu.Q NETs commercialization prospects across acute and chronic disease diagnostics.
1. Study Findings
Researchers at the Mayo Clinic analyzed blood samples from 674 trauma patients and found early post-injury elevations in Nu.Q H3.1 and H3R8 Citrulline nucleosome levels, with the highest concentrations observed in patients who developed venous thromboembolism.
2. Clinical Implications
These validated biomarkers offer potential for early identification of high-risk trauma patients, enabling targeted preventive strategies and monitoring to reduce VTE-related complications in emergency and surgical settings.
3. Commercialization Impact
Peer-reviewed validation of Nu.Q NETs strengthens VolitionRx’s case for regulatory approvals and market adoption, supporting commercial launch efforts and enhancing the company’s epigenetic diagnostics portfolio.